The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.

European cardiology Pub Date : 2022-01-28 eCollection Date: 2022-02-01 DOI:10.15420/ecr.2021.57
Nesan Shanmugam
{"title":"The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.","authors":"Nesan Shanmugam","doi":"10.15420/ecr.2021.57","DOIUrl":null,"url":null,"abstract":"© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":" ","pages":"e01"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/cb/ecr-17-e01.PMC8819603.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2021.57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2021年欧洲心力衰竭指南:个体化治疗的案例
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Early Sodium-Glucose Cotransporter 2 Inhibitor Initiation During Hospitalisation: Viewpoint on the DAPA ACT HF-TIMI 68 Trial. OPTIMA-AF: Adding Fuel to the Fire Towards Minimal Combined Antithrombotic Regimens. ADAPT AF-DES and the Limits of Non-inferiority in Long-term Antithrombotic Therapy. Glycoprotein IIb/IIIa Blockade: Ready to CELEBRATE a New Dawn? Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1